Enzo Biochem (ENZ) Reports Q2 EPS of $0.09, CEO to Step Down
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
March 15, 2021 4:05 PM EDTTotal second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemicSecond quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-yearAchieved adjusted EBITDA at $4.3 million for the quarter with increases in sequential and YOY profitabilityEPS of $0.05 for the quarter vs. EPS loss of ($0.16) in Q2 2020Dr. Elazar Rabbani, Founder and CEO, to step down as CEO and transition... More
